GlassScriptPhysician profile
Christopher Jason Crist
NPI 1598051856
$4,292.25
in general payments reported to CMS, 2019-2025
18 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,707 · 2020: $549 · 2021: $616 · 2022: $264 · 2023: $351 · 2024: $465 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,571.48 | 2019-2025 | Cabenuva |
| Gilead Sciences, INC. | $725.49 | 2019-2025 | Biktarvy |
| Astellas Pharma US INC | $462.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $344.93 | 2019-2025 | Pifeltro, Capvaxive |
| Allergan, INC. | $333.76 | 2019-2020 | |
| Melinta Therapeutics, LLC | $164.78 | 2021-2025 | Rezzayo |
| Insmed, INC. | $160.89 | 2019-2020 | |
| Shionogi INC | $116.83 | 2021 | |
| Abbvie INC. | $110.63 | 2019-2022 | |
| Cepheid | $83.61 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $58.16 | 2019-2020 | |
| Verastem, INC. | $34.39 | 2019 | |
| Soleno Therapeutics, INC. | $33.08 | 2025 | Vykat Xr |
| Biomerieux INC | $26.10 | 2025 | |
| Aimmune Therapeutics, INC. | $20.62 | 2025 | Vowst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $18.89 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.59 | 2025 | Nuzyra |
| Pfizer INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Crist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.